Download PDF
Dtsch Med Wochenschr 2013; 138(13): 665-666
DOI: 10.1055/s-0032-1332928
Kommentar | Commentary
Pharmakotherapie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Forschungsprojekte zur Förderung individualisierter Medizin in der Klinik

Research projects for implementation of individualized medicine
W. Lieb
1   Institut für Epidemiologie der Christian-Albrechts Universität Kiel
,
H. J. Grabe
2   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsmedizin Greifswald
,
H. K. Kroemer
3   Vorstand Forschung und Lehre/Dekan, Universitätsmedizin Göttingen
› Author Affiliations
Further Information

Publication History

18 January 2013

28 February 2013

Publication Date:
19 March 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

individualisierte Medizin - personalisierte Therapie - Forschungsprojekte - Datenschutz

Keywords

individualized medicine - personalized therapy - research projects - data security
 

  • Literatur

  • 1 Deloukas P, Kanoni S, Willenborg C et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2012; 45: 25-33
    CrossrefPubMedGoogle Scholar
  • 2 Hüsing B, Hartig J, Bührlen B et al. Individualisierte Medizin und Gesundheitssystem. TAB-Arbeitsbericht 2008; Nr. 126
    PubMedGoogle Scholar
  • 3 Kote-Jarai Z, Olama AA, Giles GG et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-791
    CrossrefPubMedGoogle Scholar
  • 4 Langanke M, Brothers KB, Erdmann P et al. Comparing different scientific approaches to personalized medicine: Research ethics and privacy protection. Personal Med 2011; 8: 437-444
    PubMedGoogle Scholar
  • 5 Lieb W, Volzke H, Pulley JM et al. Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin Pharmacol Ther 2012; 92: 443-445
    CrossrefPubMedGoogle Scholar
  • 6 Naj AC, Jun G, Beecham GW et al. Common variants at ms4a4/ms4a6e, cd2ap, cd33 and epha1 are associated with late-onset alzheimer's disease. Nat Genet 2011; 43: 436-441
    CrossrefPubMedGoogle Scholar
  • 7 Roden DM, Pulley JM, Basford MA et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008; 84: 362-369
    CrossrefPubMedGoogle Scholar
  • 8 Roden DM, Wilke RA, Kroemer HK et al. Pharmacogenomics: The genetics of variable drug responses. Circulation 2011; 123: 1661-1670
    CrossrefPubMedGoogle Scholar
  • 9 Rudnik-Schöneborn S, Langanke M, Erdmann P et al. Ethische und rechtliche Aspekte im Umgang mit genetischen Zufallsbefunden – Herausforderungen und Lösungsansätze. Ethik in der Medizin 2013; im Druck
    PubMedGoogle Scholar
  • 10 Siewert U, Fendrich K, Doblhammer-Reiter G et al. Health care consequences of demographic changes in mecklenburg-west pomerania: Projected case numbers for age-related diseases up to the year 2020, based on the Study of Health in Pomerania (SHIP). Dtsch Ärztebl int 2010; 107: 328-334
    PubMedGoogle Scholar
  • 11 Zhang Q, Fillmore TL, Schepmoes AA et al. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes. J exp Med 2013; 210: 191-203
    CrossrefPubMedGoogle Scholar